Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Other Non-Current Liabilities (2016 - 2025)

Arcadia Biosciences' Other Non-Current Liabilities history spans 12 years, with the latest figure at $1.0 million for Q1 2025.

  • For Q1 2025, Other Non-Current Liabilities fell 50.0% year-over-year to $1.0 million; the TTM value through Mar 2025 reached $1.0 million, down 50.0%, while the annual FY2024 figure was $2.0 million, 0.0% changed from the prior year.
  • Other Non-Current Liabilities reached $1.0 million in Q1 2025 per RKDA's latest filing, down from $2.0 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $2.1 million in Q1 2021 to a low of $1.0 million in Q1 2025.
  • Average Other Non-Current Liabilities over 5 years is $2.0 million, with a median of $2.0 million recorded in 2022.
  • Peak YoY movement for Other Non-Current Liabilities: rose 7.0% in 2021, then tumbled 50.0% in 2025.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $2.1 million in 2021, then decreased by 3.38% to $2.0 million in 2022, then changed by 0.0% to $2.0 million in 2023, then changed by 0.0% to $2.0 million in 2024, then crashed by 50.0% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for RKDA's Other Non-Current Liabilities are $1.0 million (Q1 2025), $2.0 million (Q4 2024), and $2.0 million (Q3 2024).